Инфликсимаб: на все ли вопросыполучены ответы за 10 лет?
Аннотация
Представлены данные о клинической эффективности инфликсимаба, его влиянии на внесуставные проявления ревматоидного артрита - васкулит, ревматоидные узлы, кардиоваскулярную патологию. Обсуждаются причины снижения эффекта терапии и возможности ее коррекции путем увеличения дозы либо уменьшения интервала между инфузиями.
Литература
1. <div><p>Насонов Е.Л. Эффективность и безопасность ингибиторов фактора некроза опухоли-〈 при ревматоидном артрите. РМЖ 2008;16,24(334):1602-10.</p><p>Сигидин Я.А., Лукина Г.В. Современные представления о патогенезе ревматоидного артрита. В кн.: Биологическая терапия в ревматологии. М., 2009;17-38.</p><p>Furst D.E., Keystone E.C., Kirkham B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl. 111):2-19.</p><p>Maini R.N., Breedveld F.C., Kalden I. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patient with RA treated with infliximob and methotrexate. Arthr Rheum 2004;50:1051-65.</p><p>Breedveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid artritis. Ann Rheum Dis 2004;63:149-55.</p><p>St. Clair E.W., van der Heijde D.M., Smolen J.S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004;50:3432-43.</p><p>Klarenbeek N.B., Guler-Yuksel M., van der Kooij S.M. et al. Clinical outcomes of four different treatment strategies in patients with recent-onset RA: 5-years results of the BeST-study. Ann Rheum Dis 2008;67(Suppl. 11):187. 8.</p><p>Van der Kooij S.M., Le Cessie S.,Goekoop-Ruiterman Y.P. et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009 Jul;68(7):1153-8.</p><p>O'Gradaigh D., Ireland D., Bord S. et al. Joint erosion in RA: interaction beetween tumor necrosis factor alfa, interleukin 1 and receptor activator of nuclear factor kB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004;63:354-9.</p><p>Unger L., Kayser M., Nь sslein H.G. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003;62:587-8.</p><p>Baeten D., De Keyser F., Veys E.M. et al. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis 2004;63:489-93.</p><p>Tutuncu Z., Kavanaugh A., Zvaifler N. et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthr Rheum 2005;52:2693-6.</p><p>Kastbom A., Bratt J., Ernestam S. et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alphablocking agents in patients with rheumatoid arthritis. Arthr Rheum 2007 Feb;56(2):448-52.</p><p>Canete J.D., Snarez B., Hernandez M.V. et al. Influence of variants of Fc gamma receptors 11 A and 111 A on the ACR and EULAR responses to anti-tumor necrosis alfa therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547-52. 15.</p><p>Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthr Rheum 2002;46:862-73.</p><p>Dixon W.G., Watson K.D., Lunt M. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum 2007;56:2905-12.</p><p>Greenberg J., Lin S., Decktor D. et al. Association of duration of TNF antagonist treatment with reduction in cardio-vascular outcomes in RA patients. Arthr Rheum 2006;54(Suppl. 9):422.</p><p>Wong M., Oakley S.P., Young L. et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84.</p><p>Wijbrandts C.A., van Leuven S.I., Boom H.D. et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21.</p><p>Morand E.F., Leech M., Bernhagen J. MIF - a new cytokine link between RA and atherosclerosis. Nat Rev Drug Discover 2006;5:399-410.</p><p>Smeets T.J., Kraan M.C., van Loon M.E. et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthr Rheum 2003;48:2155-62.</p><p>Park Y.B., Choi H.K., Kim M.Y. et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188-93. 23.</p><p>Van Halm V.P., Nielen M.M.,Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.</p><p>Yamamoto T., Chikugo T., Tanaka Y. Elevated plasma levels of beta-thromboglobulin and platelet factor 4 in patients with rheumatic disorders and cutaneous vasculitis. Clin Rheumatol 2002;21:501-4.</p><p>Trocmе C., Marotte H., Baillet A. et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009;68:1328-33.</p><p>Stern R., Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.</p><p>Ariza-Ariza R., Navarro-Sarabia F., Hernаndez-Cruz B. et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007;46:529-32.</p><p>Pavelka R., Jarosova K., Suchy D. et al. Increasing the infliximab dose in rheumatoid artritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-89. 29.</p><p>Van Vollenhoven R.F. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 2009;68:1237-9.</p><p>Durez P., van den Bosch F., Corluy L. et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatol 2005;44:465-8.</p><p>Takenchi T., Miyasaka N., Inoe K. Imact of trough serum level or radiographic and clinical response to infliximab plus metotrexate in patients with rheumatoid arthritis: results from RISING study. Mod Rheumatol 2009;19:478-87.</p><p>Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45. 33.</p><p>Van der Cruyssen B., Westhoven R.,Durez P. et al. Tapering infliximab dosage after temporary dose increase does not effect treatment survival in an established RA population. Ann Rheumat Diseas 2007;66(Suppl. 11):193-4.</p><p>Rahman M.U., Strusberg I., Gensens P. et al. Double-blinded in infliximab dose escalation in pathients with Rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8.</p><p>Barrera P., Oyen W.J., Boerman O.C. et al. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:825-8.</p><p>Nikas S.N., Temekonidis T.I., Zikou A.K. et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis 2004;63:102-3.</p></div><br />
Для цитирования:
Балабанова Р.М., Балабанова Р.М. Инфликсимаб: на все ли вопросыполучены ответы за 10 лет? Современная ревматология. 2010;4(1):61-65. https://doi.org/10.14412/1996-7012-2010-589
For citation:
Balabanova R.M., Balabanova R.M. INFLIXIMAB: HAVE ALL QUESTIONS BEEN ANSWERED FOR 10 YEARS? Modern Rheumatology Journal. 2010;4(1):61-65. (In Russ.) https://doi.org/10.14412/1996-7012-2010-589
Просмотров: 707
Послать статью по эл. почте 